{"id":9334,"date":"2019-12-16T14:05:59","date_gmt":"2019-12-16T13:05:59","guid":{"rendered":"https:\/\/forum.schreiner-group.com\/?p=9334"},"modified":"2022-02-28T09:03:06","modified_gmt":"2022-02-28T08:03:06","slug":"syringe-blinding-for-clinical-trial-from-sanofi","status":"publish","type":"post","link":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/","title":{"rendered":"Syringe-Blinding for Clinical Trial from Sanofi"},"content":{"rendered":"<section class=\"wpb-content-wrapper\"><p>[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221; content_placement=&#8221;top&#8221; css=&#8221;.vc_custom_1639660418653{margin-top: 150px !important;}&#8221; parallax_background_image=&#8221;9310&#8243;][vc_column][vc_empty_space height=&#8221;615px&#8221;][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1596612545427{background-color: #ffffff !important;}&#8221; el_class=&#8221;article_bighead&#8221;][vc_column][vc_custom_heading text=&#8221;SCHREINER MEDIPHARM&#8221; font_container=&#8221;tag:h2|text_align:center&#8221; use_theme_fonts=&#8221;yes&#8221; el_class=&#8221;topcategory&#8221;][vc_custom_heading text=&#8221;Syringe-Blinding for Clinical Trial from Sanofi&#8221; font_container=&#8221;tag:h1|text_align:center&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1594633744978{padding-bottom: 3% !important;}&#8221;][vc_column][vc_column_text]<strong>It is important to reliably ensure that active drug and placebo cannot be distinguished from one another during blinded clinical trials for investigational products. At the same time, there is a legal obligation to provide extensive product information in different languages for the drug being tested. This presents a particular challenge for labeling, especially when transparent containers with small radii are involved. Schreiner MediPharm has developed a special solution for syringes together with the Clinical Trial Supplies Unit of Sanofi, one of the leading global healthcare companies. <\/strong>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]For use in clinical trials, the label must provide sufficient space for comprehensive text. In addition, it must ensure that each investigational product has the same appearance, even in transparent syringe barrels. Depending on the required amount of text, a one- or two-layered wrap design is used, each of which allows double sided printing per layer of film. Extensive, high opacity printing of the transparent material is required to do this.[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1634221810619{padding-bottom: 3% !important;}&#8221;][vc_column width=&#8221;2\/3&#8243;][vc_column_text]The product solutions are based on a particularly long, one-layered wrap-around label (Pharma-Wrap) and a two-layered label (Euro-Label). Very flexible film material is required, so that the label can be easily wrapped around the syringe with a small radius. The part of the label that is directly glued to the syringe consists of a tinted transparent foil. This enables reliable neutralization of the syringe without obstructing the view of the contents. The remaining part of the label is printed on a white background, so that information can be provided on both sides. The integrated peel-open tab enables easy opening and closing of the label.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;][vc_empty_space height=&#8221;18px&#8221;][vc_single_image image=&#8221;9312&#8243; img_size=&#8221;full&#8221; add_caption=&#8221;yes&#8221; onclick=&#8221;link_image&#8221; css_animation=&#8221;fadeIn&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]These specialty labels increase flexibility, efficiency, and safety for the execution of clinical trials, because one single label variant can be used globally for labeling the respective product.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>For the successful performance of clinical trials, the following criteria are essential: accuracy, safety, efficiency and speed. Since most studies are conducted internationally, the investigational drugs must be reliably marked and provided with a complete set of important information in several languages. Pharmaceutical corporation Sanofi specified these requirements for a label the company needed for a needle protection system to be used in a phase III clinical trial\u2014and Schreiner MediPharm\u2019s CTS team found the solution precisely meeting these needs.<\/p>\n","protected":false},"author":2,"featured_media":9312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[187],"tags":[200],"class_list":["post-9334","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-schreiner-medipharm-en","tag-marking-solutions"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Syringe-Blinding for Clinical Trial from Sanofi - Schreiner Group Forum<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syringe-Blinding for Clinical Trial from Sanofi - Schreiner Group Forum\" \/>\n<meta property=\"og:description\" content=\"For the successful performance of clinical trials, the following criteria are essential: accuracy, safety, efficiency and speed. Since most studies are conducted internationally, the investigational drugs must be reliably marked and provided with a complete set of important information in several languages. Pharmaceutical corporation Sanofi specified these requirements for a label the company needed for a needle protection system to be used in a phase III clinical trial\u2014and Schreiner MediPharm\u2019s CTS team found the solution precisely meeting these needs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/\" \/>\n<meta property=\"og:site_name\" content=\"Schreiner Group Forum\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-16T13:05:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-28T08:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"markus.liedl@schreiner-group.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"markus.liedl@schreiner-group.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/\",\"url\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/\",\"name\":\"Syringe-Blinding for Clinical Trial from Sanofi - Schreiner Group Forum\",\"isPartOf\":{\"@id\":\"https:\/\/forum.schreiner-group.com\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg\",\"datePublished\":\"2019-12-16T13:05:59+00:00\",\"dateModified\":\"2022-02-28T08:03:06+00:00\",\"author\":{\"@id\":\"https:\/\/forum.schreiner-group.com\/de\/#\/schema\/person\/bd0e2515cfe9118ea30379405cb6f7dc\"},\"breadcrumb\":{\"@id\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#primaryimage\",\"url\":\"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg\",\"contentUrl\":\"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/forum.schreiner-group.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syringe-Blinding for Clinical Trial from Sanofi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/forum.schreiner-group.com\/de\/#website\",\"url\":\"https:\/\/forum.schreiner-group.com\/de\/\",\"name\":\"Schreiner Group Forum\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/forum.schreiner-group.com\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/forum.schreiner-group.com\/de\/#\/schema\/person\/bd0e2515cfe9118ea30379405cb6f7dc\",\"name\":\"markus.liedl@schreiner-group.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/forum.schreiner-group.com\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e83202ed81ba95ae0113c3f2d897918a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e83202ed81ba95ae0113c3f2d897918a?s=96&d=mm&r=g\",\"caption\":\"markus.liedl@schreiner-group.com\"},\"url\":\"https:\/\/forum.schreiner-group.com\/en\/author\/markus-liedlschreiner-group-de\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syringe-Blinding for Clinical Trial from Sanofi - Schreiner Group Forum","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/","og_locale":"en_US","og_type":"article","og_title":"Syringe-Blinding for Clinical Trial from Sanofi - Schreiner Group Forum","og_description":"For the successful performance of clinical trials, the following criteria are essential: accuracy, safety, efficiency and speed. Since most studies are conducted internationally, the investigational drugs must be reliably marked and provided with a complete set of important information in several languages. Pharmaceutical corporation Sanofi specified these requirements for a label the company needed for a needle protection system to be used in a phase III clinical trial\u2014and Schreiner MediPharm\u2019s CTS team found the solution precisely meeting these needs.","og_url":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/","og_site_name":"Schreiner Group Forum","article_published_time":"2019-12-16T13:05:59+00:00","article_modified_time":"2022-02-28T08:03:06+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg","type":"image\/jpeg"}],"author":"markus.liedl@schreiner-group.com","twitter_card":"summary_large_image","twitter_misc":{"Written by":"markus.liedl@schreiner-group.com","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/","url":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/","name":"Syringe-Blinding for Clinical Trial from Sanofi - Schreiner Group Forum","isPartOf":{"@id":"https:\/\/forum.schreiner-group.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#primaryimage"},"image":{"@id":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#primaryimage"},"thumbnailUrl":"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg","datePublished":"2019-12-16T13:05:59+00:00","dateModified":"2022-02-28T08:03:06+00:00","author":{"@id":"https:\/\/forum.schreiner-group.com\/de\/#\/schema\/person\/bd0e2515cfe9118ea30379405cb6f7dc"},"breadcrumb":{"@id":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#primaryimage","url":"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg","contentUrl":"https:\/\/forum.schreiner-group.com\/wp-content\/uploads\/2021\/12\/SMP-Booklet-Label_Nadelschutzsystem.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/forum.schreiner-group.com\/en\/syringe-blinding-for-clinical-trial-from-sanofi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/forum.schreiner-group.com\/en\/"},{"@type":"ListItem","position":2,"name":"Syringe-Blinding for Clinical Trial from Sanofi"}]},{"@type":"WebSite","@id":"https:\/\/forum.schreiner-group.com\/de\/#website","url":"https:\/\/forum.schreiner-group.com\/de\/","name":"Schreiner Group Forum","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/forum.schreiner-group.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/forum.schreiner-group.com\/de\/#\/schema\/person\/bd0e2515cfe9118ea30379405cb6f7dc","name":"markus.liedl@schreiner-group.com","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/forum.schreiner-group.com\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e83202ed81ba95ae0113c3f2d897918a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e83202ed81ba95ae0113c3f2d897918a?s=96&d=mm&r=g","caption":"markus.liedl@schreiner-group.com"},"url":"https:\/\/forum.schreiner-group.com\/en\/author\/markus-liedlschreiner-group-de\/"}]}},"_links":{"self":[{"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/posts\/9334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/comments?post=9334"}],"version-history":[{"count":8,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/posts\/9334\/revisions"}],"predecessor-version":[{"id":9473,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/posts\/9334\/revisions\/9473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/media\/9312"}],"wp:attachment":[{"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/media?parent=9334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/categories?post=9334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forum.schreiner-group.com\/en\/wp-json\/wp\/v2\/tags?post=9334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}